Raymond James Financial
XBIT icon

Raymond James Financial’s XBiotech XBIT Stock Holding History

Raymond James Financial’s Portfolio XBIT Stock Details XBIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-358
Closed -$1.06K – 6801
2025
Q2 		$1.06K Buy
+358
New +$1.04K ﹤0.01% 6553

Other funds holding XBIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Raymond James Financial's XBIT Position: Q3 2025 in Review

Raymond James Financial sold out of XBiotech (XBIT) in Q3 2025, closing a stake of 358 shares — an estimated $1.06K sold.

Raymond James Financial first reported a position in XBIT in Q2 2025 and held it in 1 quarter. The position peaked at $1.06K in Q2 2025. 48 funds tracked by Wall St. Rank hold XBIT as of Q3 2025.

  • Raymond James Financial reported no remaining XBiotech position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 358 XBiotech shares in Q3 2025, an estimated $1.06K.
  • Raymond James Financial first reported a position in XBiotech in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's XBiotech position peaked at $1.06K in Q2 2025.
  • 48 funds tracked by Wall St. Rank held XBiotech as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.